Julie M. Cherrington, PhD
Chief Executive Officer
Julie M Cherrington, PhD is currently the Chief Executive Officer of QUE Oncology, a clinical stage company developing novel non-hormonal treatments for vasomotor symptoms in postmenopausal women, and in cancer patients receiving hormone therapy; a position she has held since September 2020. She has served on the QUE Board of Directors since July 2019. Dr Cherrington, is an experienced life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®.
Dr. Cherrington previously served as President and Chief Executive Officer of Arch Oncology, a clinical-stage immuno-oncology company developing novel anti-CD47 mAbs. Previously, she has served as President and Chief Executive Officer at several other oncology companies, including Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation, a diabetes and antiviral company. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.
Dr. Cherrington is a member of the Scientific Advisory Board of the Clearity Foundation and is an advisor in entrepreneurship initiatives at CLSI, UC San Francisco, UC Davis and Equalize 2020 and 2021. Currently, she serves on the Boards of Sardona Therapeutics, Rakovina Therapeutics, QUE Oncology and Mirati Therapeutics.
Amanda Vrselja, PhD
Dr Amanda Vrselja, Clinical Scientist at QUE Oncology, has 6 years of preclinical and clinical research experience. Amanda has a Bachelor of Science (Honours) and a PhD in Developmental Biology from Monash University. Amanda represented Monash University at a STEM lecture series in Hong Kong and presented her research findings at national and international meetings, including at the University of Edinburgh, University of Oxford and Kings College London. During her PhD, Amanda developed her interest in entrepreneurship, innovation, and commercialization and was a member of the winning team in the inaugural Australian-French Entrepreneurship Challenge.
Ian Holmes, PhD
Medicinal Chemistry and Preclinical Development
Dr Ian Holmes is a Medicinal Chemist with over 20 years of drug discovery experience gained in both the pharmaceutical industry and biotech sector. Ian worked for 10 years as a Medicinal Chemist and Preclinical Project Leader with GlaxoSmithKline, UK and Zeneca, UK, before moving to Australia to become the Director of Chemistry at the Cancer Therapeutics Cooperative Research Centre, Melbourne. Subsequently moving into the biotech sector, Ian co-founded MecRx and Foray Therapeutics and currently advises companies including Azura Ophthalmics, Certa Therapeutics, OccuRx, Ena Respiratory, Axelia and Que Oncology.
Working in a number of therapeutic areas including respiratory, psychiatry, oncology and anti-infectives, Ian has contributed to the development of clinical candidates for the treatment of COPD, fibrosis, multiple types of cancer and viral infections.
Ian has a Bachelor of Science (Honours) in Chemistry and a PhD in Synthetic Organic Chemistry from the University of Nottingham, UK. He carried out postdoctoral research at the Universities of South Paris, France and Sheffield, UK. Ian is a Chartered Chemist (CChem) and Fellow of the Royal Society of Chemistry (FRSC).
Joyce James, PhD
Preclinical Development and Clinical Pharmacology
Joyce James, Ph.D., is a strong leader with over twenty years of industry experience dedicated to the discovery and development of therapeutics, including small molecules, peptides and biologics. Areas of expertise include nonclinical, early phase clinical trials, and bioanalytical, biomarker and pharmacodynamic assays to support all stages of development, including related development and regulatory strategy. Founder of Corvid LLC, an early development and clinical pharmacology consulting company. Previously served as Vice President of Early Development and member of the management team for Odonate Therapeutics, an oncology focused company. Founding and core member of Lyric Pharmaceuticals, serving as Vice President, Clinical Pharmacology & Early Development. Prior to Lyric, served as Senior Director and Head of Drug Metabolism and Pharmacokinetics & Analytical Chemistry at Cytokinetics, supporting numerous research and clinical programs. Held senior positions at Ambit Biosciences, playing a key role in the discovery and development of quizartinib for the treatment of FLT3-ITD positive acute myelogenous leukemia (approved in Japan). Provided critical support for the successful filing of multiple INDs and deep experience in nonclinical and clinical Phase 1 study designs. Consult for a number of biopharmaceutical companies providing ADME, analytical, clinical pharmacology, and bioanalytical support. Began pharmaceutical career as a Research Fellow at Merck Research Labs, devoting time to both NMR spectroscopy and discovery DMPK. Ph.D. in Biophysical Chemistry, The University of California, Berkeley, Department of Chemistry and B.S. in Biochemistry, The College of Charleston, Department of Chemistry, summa cum laude.
Alan Parr, Pharm.D, PhD
Dr Alan Parr, Head of CMC at Que Oncology, has worked in the field of Pharmaceutical Sciences for 33 years including with Glaxo, GlaxoWellcome and GlaxoSmithKline. As formulation scientist, formulation manager, and eventually as Director of Biopharmaceutics with GSK. Responsibilities ranged from development of formulations from early development phase all the way through to the scale up of commercial size batches for the marketplace. Specific activities during this time have included physical property characterization, formulation screening, formulation development, manufacture of clinical supplies, transfer of product to production and overall project management. He has been intimately involved with the creation, review and submission of regulatory documents to the US Food and Drug Administration, including Investigational New Drug (IND) applications, New Drug Applications (NDA) as well as foreign filings (Marketing Authorization Applications (MAA)).
Gary A. Shangold, MD
Gary Shangold, MD is the founder and CEO of InteguRx Therapeutics, a company developing transdermal pharmaceutical products based on a novel proprietary penetration-enhancement system. He is also President of Convivotech, a consultancy to Life Sciences companies, and Chief Medical Officer of Enteris BioPharma Inc, a wholly-owned subsidiary of SWK Holdings (Nasdaq: SWKH) which is developing oral formulations of peptides and other BCS Class III and IV small molecules.
He was formerly Chief Medical Officer / Executive VP for R&D at Xanodyne Pharmaceuticals. Before that, he was President & CEO of NovaDel Pharma, a publicly-traded specialty pharma company. Earlier still, he worked at Johnson & Johnson Pharmaceutical R&D, where he held several senior roles in Clinical Research and Regulatory Affairs. Prior to J&J, Dr. Shangold was Medical Director for Ob/Gyn/Infertility at Serono Laboratories US.
Before his 30 years in the pharma industry, Dr. Shangold spent a decade in academia, on the faculty of The Univ. of Chicago Pritzker School of Medicine, and then later at Massachusetts General Hospital and the Harvard School of Medicine.
He has previously served as President of the American Academy of Pharmaceutical Physicians, and as Chair of the Association of Clinical Research Professionals, a 14,000-member nonprofit dedicated to excellence and professionalism in clinical research globally.
Dr. Shangold completed an Ob/Gyn residency at Jackson Memorial Hospital / Univ. of Miami and a fellowship in Reproductive Endocrinology at the L.A. County / Univ. of Southern California Medical Center. He received a BA in Social Behavior from the University of Pennsylvania, and an MD from the Columbia University College of Physicians and Surgeons.
Michael Walker, PhD
Michael Walker, Biostatistics Consultant at Que Oncology, received his Ph.D. from Stanford University, and has taught statistics and clinical trial design at Stanford and UC San Diego for 25 years. He provides statistics and clinical trial consulting for diverse pharmaceutical and biotechnology companies. His FDA experience includes IND, NDA, IDE, 510k, PMA, SPA and other submissions. He has published in the New England Journal of Medicine and in Lancet and has developed products with over one billion dollars in revenues.
Gregory Wilson, MBA
Mr. Wilson is a consulting CFO specializing in providing financial and administrative consulting services primarily to venture-backed, start-up companies. He has more than 30 years’ experience in a variety of companies ranging from start-up to Fortune 500, public to private, and domestic to international. Mr. Wilson currently specializes in life science companies in biotechnology and medical devices. Current clients include Que Oncology, OncoSynergy, Aqua Medical, and Aqua Heart. Former clients include CytomX Therapeutics (CTMX), Afferent Pharmaceuticals (acquired by Merck), Ablexis (acquired by Deerfield), Primaeva Medical (acquired by Syneron), Sapphire Medical (acquired by Tornier), BARRx Medical (acquired by Covidien), Protexis (acquired by Bertelsmann AG), and Xros (acquired by Nortel). Prior to consulting, he was CFO at Micronics Computers (acquired by Diamond Multimedia) and Dynamic Isolation Systems (acquired by Berwind). Mr. Wilson’s early finance career was with Gates Corporation, the majority owner of LearJet. He has an MBA in Accounting from the University of Colorado, a BS in Biological Science from Colorado State University and is a CPA (inactive).